Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 Therapies

Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.

Related Videos
Experts on RCC
Experts on RCC
Experts on RCC
Experts on RCC
Experts on MM
Related Content